ImmunoGen said it is
planning a new offering of stock. The Waltham-based company, which develops cancer treatments, said Friday that it has priced an underwritten public offering of 6.25 million shares of common stock at $16 per share. Gross proceeds are expected to be about $100
million. The offering is expected to close on Tuesday.
Morgan Stanley & Co. and
Jefferies & Co. are acting as joint book-running managers for the offering.